시장보고서
상품코드
1193269

세계의 피브린 실란트 시장 : 제형별, 용도별, 최종 사용자별 기회 분석 및 산업 예측(2021-2031년)

Fibrin Sealants Market By Dosage Forms, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2021-2031

발행일: | 리서치사: Allied Market Research | 페이지 정보: 영문 248 Pages | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

피브린 실란트(Fibrin Sealants)는 주로 지혈제로서, 또한 조직 봉쇄 및 상처 치유를 보조하는 목적으로 다양한 수술에 사용됩니다.

피브린 실란트는 공기 및 액체 누출과 같은 수술 합병증을 피하기 위해 수술 중에 사용됩니다. 필름상, 분말상, 액상 형태의 제품이 지혈층을 형성하여 환부로부터 혈액이나 공기 누출을 멈춥니다.

피브린 실란트에는 피브리노겐과 트롬빈이 포함되어 있지만 최종 조성은 다릅니다. 이것은 생성되는 피브린 덩어리 특성에 영향을 미치고 다양한 수술 절차 사용에 영향을 줄 수 있습니다. 피브리노겐을 고농도로 함유하는 피브린 실란트는 보다 견고한 혈전을 형성하는 경향이 있으며, 트롬빈을 고농도로 포함하는 것은 혈전을 신속하게 형성합니다.

피브린 실란트 시장 성장을 주도하는 주요 요인은 기술 진보 상승, 심장 질환, 암, 허혈성 뇌졸중, 동맥류 등 만성 질환 유병률 증가, 교통 사고 증가 등 수술을 위한 피브린 실란트의 높은 선호 등을 포함합니다.

예를 들어 세계의 보건기구에 따르면, 심혈관 질환(CVDs)은 매년 1790만 명의 생명을 앗아가는 것으로 추정되는 세계의 첫 번째 사망 원인입니다. 2020년 약 1,790만 명이 매년 CVD 사망할 것으로 추정되며, 이는 세계의 사망자 수 약 31%에 해당합니다. 예를 들어 국립건강통계센터에 따르면 미국은 매년 약 805,000명이 심장 발작을 일으키고 있습니다. 이 때문에 심장 수술 건수가 증가하고 피브린 실란트 사용도 증가하고 있습니다.

그러나 피브린 실란트 제품과 관련된 높은 비용과 같은 합병증과 마찬가지로 불리한 상환은 시장 성장을 방해할 것으로 예상됩니다. 반대로, 개발도상국의 충족되지 않은 의료 수요와 신흥 국가의 유리한 기회는 미래에 세계의 피브린 실런트 제조업체를 위한 거대한 기회를 만들 것으로 기대됩니다.

또한 건강 관리 사업은 심장 우회 수술, 암 수술, 고형 종양 수술, 신경 혈전 절제술, 장기 이식 수술 등 수술 증가, 고급 피브린 실란트 발견 및 개발 R&D 투자 증가 및 수술시 혈액 손실을 줄이기 위해 피브린 실란트를 사용하는 경향 증가로 인해 성장을 나타낼 것으로 예상됩니다. 이 때문에 주요 기업이 시장에 투자함으로써 유익한 기회를 제공할 수 있을 것으로 예상됩니다.

목차

제1장 소개

제2장 주요 요약

제3장 시장 주요 요약

  • 시장 정의와 범위
  • 주요 조사 결과
    • 주요 투자 포켓
  • 포터의 5가지 경쟁요인 분석
  • 주요 기업 포지셔닝
  • 시장 역학
    • 촉진 요인
    • 억제 요인
    • 기회
  • COVID-19 영향 분석

제4장 피브린 실란트 시장 : 제형별

  • 주요 요약
    • 시장 규모 및 예측
  • 리퀴드
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모, 예측 : 지역별
    • 시장 분석 : 국가별
  • 패치
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모, 예측 : 지역별
    • 시장 분석 : 국가별
  • 파우더
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모, 예측 : 지역별
    • 시장 분석 : 국가별

제5장 피브린 실란트 시장 : 용도별

  • 주요 요약
    • 시장 규모 및 예측
  • 일반 외과용
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모, 예측 : 지역별
    • 시장 분석 : 국가별
  • 심장 혈관 수술
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모, 예측 : 지역별
    • 시장 분석 : 국가별
  • 상처 관리
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모, 예측 : 지역별
    • 시장 분석 : 국가별
  • 정형외과
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모, 예측 : 지역별
    • 시장 분석 : 국가별
  • 비뇨기과 수술
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모, 예측 : 지역별
    • 시장 분석 : 국가별
  • 안과 수술
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모, 예측 : 지역별
    • 시장 분석 : 국가별
  • 기타
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모, 예측 : 지역별
    • 시장 분석 : 국가별

제6장 피브린 실란트 시장 : 최종 사용자별

  • 주요 요약
    • 시장 규모, 예측
  • 병원
    • 주요 시장 동향, 성장 요인과 기회
    • 시장 규모, 예측 : 지역별
    • 시장 분석 : 국가별
  • 외래 수술 센터
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모, 예측 : 지역별
    • 시장 분석 : 국가별
  • 진료소
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모, 예측 : 지역별
    • 시장 분석 : 국가별

제7장 피브린 실란트 시장 : 지역별

  • 주요 요약
    • 시장 규모, 예측
  • 북미
    • 주요 동향과 기회
    • 북미 시장 규모, 예측 : 제형별
    • 북미 시장 규모, 예측 : 용도별
    • 북미 시장 규모, 예측 : 최종 사용자별
    • 북미 시장 규모, 예측 : 국가별
      • 미국
      • 캐나다
      • 멕시코
  • 유럽
    • 주요 동향과 기회
    • 유럽 시장 규모, 예측 : 제형별
    • 유럽 시장 규모, 예측 : 용도별
    • 유럽 시장 규모, 예측 : 최종 사용자별
    • 유럽 시장 규모, 예측 : 국가별
      • 독일
      • 프랑스
      • 영국
      • 이탈리아
      • 스페인
      • 기타 유럽
  • 아시아태평양 지역
    • 주요 동향과 기회
    • 아시아태평양 지역 시장 규모, 예측:제형별
    • 아시아태평양 지역 시장 규모, 예측 : 용도별
    • 아시아태평양 지역 시장 규모, 예측 : 최종 사용자별
    • 아시아태평양 지역 시장 규모, 예측 : 국가별
      • 일본
      • 중국
      • 인도
      • 호주
      • 한국
      • 기타 아시아태평양 지역
  • LAMEA
    • 주요 동향과 기회
    • LAMEA 시장 규모, 예측 : 제형별
    • LAMEA 시장 규모, 예측 : 용도별
    • LAMEA 시장 규모, 예측 : 최종 사용자별
    • LAMEA 시장 규모, 예측 : 국가별
      • 브라질
      • 남아프리카 공화국
      • 사우디 아라비아
      • LAMEA 이외 지역

제8장 기업 정세

  • 소개
  • 주요 성공 전략
  • 주요 10개사 제품 매핑
  • 경쟁 대시보드
  • 경쟁 히트맵
  • 주요 발전

제9장 기업 프로필

  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Corza Medical
  • CSL Behring
  • Grifols
  • hemarus therapeutics ltd.
  • Johnson and Johnson
  • Nordson Corporation(Nordson Medical)
  • Shanghai RAAS Blood Products Co., Ltd.
  • vivostat a/s
NJH 23.03.15

Fibrin sealants are used in a wide range of surgeries, primarily as hemostatic agents, however, also to assist tissue sealing and wound healing. Fibrin sealants are used during surgeries to avoid surgical complications such as air and fluid leaks. These sealants are available in the form of films, powder and liquid, and aid by creating a hemostatic layer, which stops blood and air leakage from the targeted area.

Fibrin sealants contain fibrinogen and thrombin, they differ in their final composition. This affects properties of the resulting fibrin clot and may influence their use in different surgical procedures. Fibrin sealants with high concentrations of fibrinogen tend to produce stronger clots, whereas those containing higher concentrations of thrombin form clots rapidly.

Major factors driving growth of the fibrin sealants market include rise in technological advancements, increase in prevalence rate of chronic diseases such as heart diseases, cancer, ischemic stroke, aneurysm, and increase in road accidents propel high adoption of fibrin sealants for these surgeries.

For instance, according to World Health Organization Cardiovascular diseases (CVDs) are leading cause of death globally, taking an estimated 17.9 million lives each year. It has been estimated in 2020 that around 17.9 million people die each year from CVDs, an estimated 31% of all deaths worldwide. For instance, according to the National Center for Health Statistics, every year, about 805,000 people in the U.S. have a heart attack. This led to increase in number cardiac surgeries and use of fibrin sealants.

However, unfavorable reimbursements as well as complications such as high costs associated with fibrin sealant products are expected to hamper the market growth. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for fibrin sealant manufacturers worldwide in the future.

Furthermore, healthcare business is projected to witness growth, owing to rise in surgeries such heart bypass surgery, cancer surgeries, solid tumor surgeries, neurothrombectomy, organ transplant surgeries, increase in R&D investments in discovery & development of advanced fibrin sealants, and rise in awareness regarding use of fibrin sealants for reducing blood loss in surgeries. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.

The fibrin sealants market is segmented on the basis of dosage form, application, end user, and region. On the basis of dosage form, the market is classified into liquid, patch, and powder. On the basis of application, it is classified into general surgery, cardiovascular surgery, wound management, orthopedic surgery, urological surgeries, ophthalmic surgeries, and others. Depending on end user, it is fragmented into hospitals, ambulatory surgical centers, and clinics. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major players profiled in the report are Baxter International Inc., Becton, Dickinson and Company, Corza Medical, CSL Behring, Grifols, S.A., Hemarus Therapeutics Ltd, Johnson and Johnson, Nordson Corporation (Nordson Medical), Shanghai RAAS Blood Products Co., Ltd., and Vivostat A/S.

KEY BENEFITS FOR STAKEHOLDERS

  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the fibrin sealants market to identify the prevailing opportunities.
  • This study presents the competitive landscape of the global market to predict the competitive environment across various regions.
  • Comprehensive analysis of factors that drive and restrict the market growth is provided.
  • Region & country wise analysis is provided to understand the market trends and dynamics.

Key Market Segments

By Dosage Forms

  • Liquid
  • Patch
  • Powder

By Application

  • General Surgery
  • Cardiovascular Surgery
  • Wound Management
  • Orthopedic Surgery
  • Urological Surgeries
  • Ophthalmic Surgeries
  • Others

By End User

  • Hospitals
  • Ambulatory Surgical Centers
  • Clinics

By Region

  • North America
    • Canada
    • Mexico
    • U.S.
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA
  • Key Market Players
    • Baxter International Inc.
    • Becton, Dickinson and Company
    • Corza Medical
    • CSL Behring
    • Grifols
    • hemarus therapeutics ltd.
    • Johnson and Johnson
    • Nordson Corporation (Nordson Medical)
    • Shanghai RAAS Blood Products Co., Ltd.
    • vivostat a/s

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: FIBRIN SEALANTS MARKET, BY DOSAGE FORMS

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Liquid
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Patch
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Powder
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country

CHAPTER 5: FIBRIN SEALANTS MARKET, BY APPLICATION

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 General Surgery
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Cardiovascular Surgery
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 Wound Management
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country
  • 5.5 Orthopedic Surgery
    • 5.5.1 Key market trends, growth factors and opportunities
    • 5.5.2 Market size and forecast, by region
    • 5.5.3 Market analysis by country
  • 5.6 Urological Surgeries
    • 5.6.1 Key market trends, growth factors and opportunities
    • 5.6.2 Market size and forecast, by region
    • 5.6.3 Market analysis by country
  • 5.7 Ophthalmic Surgeries
    • 5.7.1 Key market trends, growth factors and opportunities
    • 5.7.2 Market size and forecast, by region
    • 5.7.3 Market analysis by country
  • 5.8 Others
    • 5.8.1 Key market trends, growth factors and opportunities
    • 5.8.2 Market size and forecast, by region
    • 5.8.3 Market analysis by country

CHAPTER 6: FIBRIN SEALANTS MARKET, BY END USER

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospitals
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Ambulatory Surgical Centers
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Clinics
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country

CHAPTER 7: FIBRIN SEALANTS MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Dosage Forms
    • 7.2.3 North America Market size and forecast, by Application
    • 7.2.4 North America Market size and forecast, by End User
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Dosage Forms
      • 7.2.5.1.2 Market size and forecast, by Application
      • 7.2.5.1.3 Market size and forecast, by End User
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Dosage Forms
      • 7.2.5.2.2 Market size and forecast, by Application
      • 7.2.5.2.3 Market size and forecast, by End User
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Dosage Forms
      • 7.2.5.3.2 Market size and forecast, by Application
      • 7.2.5.3.3 Market size and forecast, by End User
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Dosage Forms
    • 7.3.3 Europe Market size and forecast, by Application
    • 7.3.4 Europe Market size and forecast, by End User
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Dosage Forms
      • 7.3.5.1.2 Market size and forecast, by Application
      • 7.3.5.1.3 Market size and forecast, by End User
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Dosage Forms
      • 7.3.5.2.2 Market size and forecast, by Application
      • 7.3.5.2.3 Market size and forecast, by End User
      • 7.3.5.3 UK
      • 7.3.5.3.1 Market size and forecast, by Dosage Forms
      • 7.3.5.3.2 Market size and forecast, by Application
      • 7.3.5.3.3 Market size and forecast, by End User
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Dosage Forms
      • 7.3.5.4.2 Market size and forecast, by Application
      • 7.3.5.4.3 Market size and forecast, by End User
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Dosage Forms
      • 7.3.5.5.2 Market size and forecast, by Application
      • 7.3.5.5.3 Market size and forecast, by End User
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Dosage Forms
      • 7.3.5.6.2 Market size and forecast, by Application
      • 7.3.5.6.3 Market size and forecast, by End User
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Dosage Forms
    • 7.4.3 Asia-Pacific Market size and forecast, by Application
    • 7.4.4 Asia-Pacific Market size and forecast, by End User
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Dosage Forms
      • 7.4.5.1.2 Market size and forecast, by Application
      • 7.4.5.1.3 Market size and forecast, by End User
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Dosage Forms
      • 7.4.5.2.2 Market size and forecast, by Application
      • 7.4.5.2.3 Market size and forecast, by End User
      • 7.4.5.3 India
      • 7.4.5.3.1 Market size and forecast, by Dosage Forms
      • 7.4.5.3.2 Market size and forecast, by Application
      • 7.4.5.3.3 Market size and forecast, by End User
      • 7.4.5.4 Australia
      • 7.4.5.4.1 Market size and forecast, by Dosage Forms
      • 7.4.5.4.2 Market size and forecast, by Application
      • 7.4.5.4.3 Market size and forecast, by End User
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Market size and forecast, by Dosage Forms
      • 7.4.5.5.2 Market size and forecast, by Application
      • 7.4.5.5.3 Market size and forecast, by End User
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Market size and forecast, by Dosage Forms
      • 7.4.5.6.2 Market size and forecast, by Application
      • 7.4.5.6.3 Market size and forecast, by End User
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Dosage Forms
    • 7.5.3 LAMEA Market size and forecast, by Application
    • 7.5.4 LAMEA Market size and forecast, by End User
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Dosage Forms
      • 7.5.5.1.2 Market size and forecast, by Application
      • 7.5.5.1.3 Market size and forecast, by End User
      • 7.5.5.2 South Africa
      • 7.5.5.2.1 Market size and forecast, by Dosage Forms
      • 7.5.5.2.2 Market size and forecast, by Application
      • 7.5.5.2.3 Market size and forecast, by End User
      • 7.5.5.3 Saudi Arabia
      • 7.5.5.3.1 Market size and forecast, by Dosage Forms
      • 7.5.5.3.2 Market size and forecast, by Application
      • 7.5.5.3.3 Market size and forecast, by End User
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Dosage Forms
      • 7.5.5.4.2 Market size and forecast, by Application
      • 7.5.5.4.3 Market size and forecast, by End User

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Baxter International Inc.
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Becton, Dickinson and Company
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Corza Medical
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 CSL Behring
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Grifols
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 hemarus therapeutics ltd.
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Johnson and Johnson
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Nordson Corporation (Nordson Medical)
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Shanghai RAAS Blood Products Co., Ltd.
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 vivostat a/s
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제